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Abstract
Objective: The objective of this selective EBM review is to determine whether or not “Is spinal
cord stimulation an effective therapy to treat severe lower extremity painful diabetic peripheral
neuropathy that has lasted over one year and has not responded to medical therapy?”
Study Design: A review of two RCTs and one case series published in English in 2014.
Data Sources: Two RCTs and one case series found via PubMed that evaluated the benefit of
spinal cord stimulation (SCS) versus best medical treatment (BMT) to treat severe painful
diabetic peripheral neuropathy (PDPN).
Outcome(s) Measured: The amount of pain a patient experiences, measured using either a
visual analogue scale with 0 representing no pain and 100 representing the worst pain
imaginable, or measured with a numeric rating scale.
Results: All three studies found a significant decrease in pain levels in patients receiving SCS
treatment for severe PDPN compared to patients receiving BMT. In the Abd-Elsayed et al. case
series, a patient with PDPN reported a 60% overall decrease in pain 1 month post SCS
implantation. In the De Vos et al. RCT, the average visual analogue scale (VAS) pain score in
patients receiving SCS was reduced from 73/100 to 31/100 (P < 0.001), while the VAS pain
score in the control group remained 67/100. 60% of patients in the SCS group experienced at
least 50% pain reduction, while only 5% of patients in the control group experienced 50% pain
reduction. In the Slangen et al. RCT, treatment success was observed in 59% of patients
receiving SCS, while success was observed only in 7% of patients receiving BMT (P < 0.01).
Conclusions: Based on these three studies, pain is significantly decreased in patients
experiencing severe PDPN when treated with spinal cord stimulation compared to best medical
therapy. The spinal cord stimulator implantation is a surgical procedure that has risks that
patients should be made aware of prior to treatment. However, in patients where benefits
outweigh the risks, SCS should be considered a treatment option for severe PDPN.
Key Words: Spinal cord stimulation, painful diabetic peripheral neuropathy, neuropathic pain
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INTRODUCTION
Diabetes Mellitus (DM) is a chronic disease that occurs when the body does not make
enough insulin or develops a resistance to insulin, leading to elevated blood glucose levels
(hyperglycemia).1 Type 1 diabetes manifests earlier in life, while type 2 manifests later, usually
from a lifetime of poor diet and lack of exercise. Uncontrolled diabetes has a variety of
complications, including stroke, heart disease, heart attack, and neuropathy. Nerve damage,
leading to painful diabetic peripheral neuropathy, may result in patients that have had diabetes
for an extended period of time or have had difficulty controlling their blood glucose levels.1 The
exact cause of PDPN is unknown, however researchers believe that diabetic neuropathies are due
to a number of factors, including: high blood glucose, abnormal blood fat levels, low insulin,
neurovascular factors, nerve inflammation, mechanical injury, genetics, and lifestyle factors.
These patients may experience numbness, tingling, burning, weakness, loss of reflexes, loss of
coordination, and pain as the nerve damage progresses.1 This can happen in any area of the body:
the arms, legs, digestive tract, and sex organs. The most common type of diabetic neuropathy
affects the periphery, which causes symptoms in arms or legs.1
It is estimated that a total of 23.1 million people in the US have a diagnosis of diabetes
and approximately 7.2 million people have diabetes but remain undiagnosed.2 These 7.2 million
people are likely to have uncontrolled blood glucose levels and are therefore at an increased risk
of developing complications of diabetes, like PDPN. It is estimated that 60-70% of patients with
diabetes will develop some type of neuropathy.1
The CDC estimates that a total of 14.2 million emergency department visits in 2014 had
diabetes listed as a diagnosis, including 207,000 visits for hyperglycemia and 245,000 visits for
hypoglycemia.2 In addition, the estimated total direct and indirect cost for diabetes is $245
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billion in the US alone. Average medical expenses are approximately 2.3 times higher in patients
with diabetes than without.2 The more complications that exist, the more the cost increases.
The first line treatment of diabetic complications is to gain and maintain control of blood
glucose levels through blood glucose monitoring, diet, exercise, and medications that help to
decrease blood glucose like Metformin and Insulin.1 It is also very important that diabetic
patients see their primary care physician and have their feet checked regularly. Most diabetic
patients have regular appointments every three to six months for blood work, including a
Hemoglobin A1c, which measures the average blood glucose level over three months. For
PDPN, pain relief can be gained through a variety of medications, including: antidepressants,
anticonvulsants, and opioid or opioid like drugs. Duloxetine and Pregabalin are approved by the
FDA specifically for treating PDPN.1 These medications often come with side effects and are not
always approved for use in older individuals. Over the counter medications such as ibuprofen
and acetaminophen generally do not work well for nerve pain. Lastly, topical treatments, like
capsaicin cream and lidocaine, are available and are most commonly applied to the feet. These
medications are relatively safe but do not necessarily provide relief.1
The above listed treatment options have been found to be the most effective medical
options thus far in treating pain associated with PDPN, and therefore are deemed the “best
medical therapy” (BMT). However, they are often accompanied by side effects and are not
effective enough in relieving pain. Several studies have shown that spinal cord stimulation has
been more effective than BMT in treating pain associated with PDPN. The mechanism of action
of spinal cord stimulation has not been fully uncovered, but it is thought to be multifactorial.3
The spinal cord level at which the SCS is placed is dependent on the location of symptoms, but is
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generally in the thoracic region. This paper evaluates two randomized controlled trials (RCTs)
and one case series that show the efficacy of SCS compared to BMT in treating severe PDPN.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is spinal cord
stimulation an effective therapy to treat severe lower extremity diabetic peripheral neuropathy
pain that has lasted over one year and has not responded to medical therapy?
METHODS
Two randomized controlled trials and one case series were used in this review. The
population includes men and women over the age of 18 with type 1 or type 2 diabetes mellitus
experiencing moderate to severe lower extremity painful diabetic peripheral neuropathy for at
least one year that has not been successfully treated by BMT. The intervention used in the two
RCTs was SCS along with BMT. The control group received BMT alone. In the case series, the
intervention was spinal cord stimulation. All three studies found a significant decrease in pain
levels in patients receiving SCS treatment for severe PDPN compared to patients receiving BMT
only.
The key words used in searching for the articles addressed in this review included the
following: diabetic neuropathy, neuropathic pain, and spinal cord stimulation. All three articles
were published in English in peer-reviewed journals. The articles were selected based on
relevance to the clinical question and if they addressed outcomes that were patient oriented
evidence that matters (POEMs). The inclusion criteria included RCTs and other studies
published after 2006. Studies that were excluded were those published before 2006, those that
involved patients less than 18 years of age, and those discussing upper extremity or mild PDPN.
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Statistics reported included the following: p-value, ABI, RRI, NNT, and NNH. Specific
demographics and characteristics of each of the studies are detailed in Table 1 below.

Table 1- Demographics and Characteristics of included studies
Study

Type

#
Pts
3

Age
(yrs)
79,
60,
39

AbdElsayed,
et al.
(2014)4
De Vos,
et al.
(2014)5

Case
Series
RCT

60

>18
years
old

Slangen,
et al.
(2014)6

RCT

36

1880
years
old

Inclusion Criteria

Exclusion Criteria

W
/D
0

Interventions

Patients with
resistant painful
peripheral
neuropathy
Patients that were
evaluated and
diagnosed with
diabetic
neuropathy by a
neurologist, had
refractory diabetic
neuropathic pain
in the lower
extremities for >1
year, and had an
average pain score
of >50 on a visual
analogue scale
(VAS).

There were no patients
excluded in this study.
Patients with pain due
to atherosclerotic
lesions, patients with
infection, neuropathic
pain in upper
extremities, coagulation
disorders or taking
anticoagulant
medication, patients
with psychiatric
disorders, and patients
addicted to drugs or
alcohol.

6

Patients with
neuropathic pain in
upper limbs,
neuropathy of origin
other than DM, recent
neuro-modulation
therapy, drug or alcohol
abuse, blood clotting
disorders, immune
deficiency, PV disease,
active foot ulcers, life
expectancy <1 year,
pacemakers, local
infection, psychiatric
disorders, pregnancy,
cardiac or pulmonary
failure, unstable
glucose control, or use
of anticoagulants.

2

Implantation of
a spinal cord
stimulator over
the physiologic
midline with the
tip of the
electrode lead
between
vertebral levels
T9 and T12.
Medication
adjustments and
PT were allowed
at any time at
the discretion of
the physician.
Implantation of
spinal cord
stimulator with
the lead
positioned over
the thoracic
level and
settings tailored
to each patient.

Patients with
moderate to severe
PDPN present in
the lower limbs,
experiencing
insufficient pain
relief and/or
unacceptable side
effects with drug
treatment, with
pain present <12
months, and a
mean pain
intensity daytime
or nighttime of >5
on a NRS.

Implantation of
a spinal cord
stimulator
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OUTCOMES MEASURED
All three studies measured pain, reported by the patients. In the Abd-Elsayed, et al. case
series, pain was measured using a visual analogue scale (VAS), from 0-10, with 0 representing
no pain and 10 representing maximum pain. Pain was measured at baseline and 1-month post
SCS implantation.4 In the De Vos, et al. RCT, pain was measured using a VAS, from 0-100, with
0 representing no pain and 100 representing the worst pain imaginable. Pain was measured at
baseline, 1 month, 3 months, and 6 months. Treatment success was defined as a greater than 50%
reduction in pain on the VAS.5 In the Slangen, et al. RCT, pain was measured using a numeric
rating scale (NRS), from 0-10, with 0 representing no pain and 10 representing maximum pain.
Pain was measured at baseline, 3 months, and 6 months. Treatment success was defined as a
greater than 50% relief of daytime or nighttime pain intensity on the NRS for at least 4 days.6
RESULTS
Two RCTs and one case series evaluated the efficacy of spinal cord stimulation as
management for painful diabetic peripheral neuropathy. The Abd-Elsayed, et al. case series
describes three patients with peripheral neuropathy: 1) a 79-year-old male with bilateral lower
extremity painful diabetic peripheral neuropathy for 11 years, 2) a 60-year-old male with HIVinduced neuropathy for 15 years, and 3) a 39-year-old female with neuropathy secondary to
chemotherapy for 3 years.4 These patients had failed best medical therapy and therefore SCS was
presented as an option to manage their pain. All three patients experienced a reduction in pain
with the one-week trial period of the spinal cord stimulator. Patient 1 and patient 3 elected to
receive the permanent SCS implantation and continued to experience pain reduction. Patient 2
did experience pain relief with the SCS trial, however his health declined and he elected to
postpone the implantation.4 The patient most relevant to this study, patient 1, reported improved
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VAS scores with the trial and after implantation reported an overall 60% pain reduction. In
addition, he reported improved activities of daily living such as walking and grocery shopping,
and breakthrough oral pain medications were successfully weaned down.4 The results are
displayed below in Table 2.
Table 2- Abd-Elsayed, et al.4 VAS scores and pain reduction
Patient
Baseline VAS
VAS score after VAS score after
pain score
1 week of trial
implantation
SCS
1
2
3

9/10
9/10
8/10

3/10
Not reported
Not reported

2/10
Not reported
Not reported

Percent
reduction in
pain from
baseline
60%
95%
95%

In De Vos, et al., a RCT, a total of 60 patients with an average VAS pain score of at least
50/100 were selected and randomized in a 2:1 fashion to either the SCS with BMT group, or the
BMT only group.5 For all patients in both groups, adjustments in BMT, including medications
and physical therapy, were allowed at any time throughout the duration of the study. All patients
were followed up at 1 month, 3 months, and 6 months to assess pain on a VAS. Two patients
failed to follow up for their 1 month visit and four patients failed to follow up at the 3 month
visit. Data analysis was performed regardless. Treatment success was defined as a greater than
50% reduction in pain.5 After 6 months, the SCS group had a 60% success rate, while the control
group had only a 5% success rate (p < 0.001), showing a significant difference in treatment effect
between groups (Table 3).5 RBI was calculated to be 11, ABI was calculated to be 0.55, and
NNT was calculated to be 2. This is significant because it means that two patients would need to
be treated in order for one patient to see a benefit compared to the control. Detailed calculations
can be seen in Table 4 below. This study was not without adverse events. A total of six patients
withdrew from the study: four from the SCS group and two from the control group. Therefore,
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the study contained 36 patients in the SCS group and 18 patients in the BMT group. From the
SCS group, one patient could not get the implant, two patients did not get any relief in the trial,
and one patient left this study for another. In the control group, two patients withdrew due to
unrelated illnesses.5 In the SCS group; there were two cases of infections, one femur fracture,
one cardiac arrest, and four patients that needed repositioning of the SCS device. In the control
group, there were two infections, one carotid artery stenosis, one myocardial infarction, one
atrial fibrillation episode, and one coronary bypass surgery. All adverse events were treated and
resolved during the study period.5
Table 3- De Vos, et al.5 treatment outcomes
VAS baseline
VAS 6 months
(out of 100)
(out of 100)
SCS group
73 (SD=16)
31 (SD= 28)*
Control group
67 (SD=18)
67 (SD=18)**

Treatment
success
60%
5%

*P<0.001, significant treatment effect within group
**P<0.001, significant treatment effect between groups
SD = standard deviation

Table 4- Calculations for treatment success from De Vos, et al.
Relative benefit
Absolute benefit
increase (RBI)
increase (ABI)
EER- CER
CER
EER
EER - CER
CER
0.05

0.60

11

0.55

Number needed to
treat (NNT)
1/ABI
2

In Slangen, et al., a RCT, 36 patients with severe PDPN not responding to best medical
therapy were randomly assigned in a 3:2 fashion to either SCS with BMT or BMT only.6
Twenty-two patients were assigned to the SCS group, while 14 were assigned to the BMT only
group. Patients were followed at 3 months and 6 months. Treatment success was defined as
greater than 50% reduction in daytime or nighttime pain for at least four days. At 6 months,
treatment success in the SCS grouped was reported in 13 out of 22 patients (59%) and 1 out of
14 (7%) in the control group (p < 0.009).5 In addition, 41% of patients in the SCS group reported
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greater than 50% daytime pain relief compared to 0% in the control group (P < 0.001), while
36% in the SCS group reported greater than 50% of nighttime pain relief compared to 7% in the
control group (P < 0.01).6 These results can be seen in Table 5. RBI was calculated to be 7.43,
ABI was calculated to be 0.52, and NNT was calculated to be 2 for treatment success. This is
significant because it means that two patients would need to be treated for one patient to see a
benefit compared to the control. Detailed calculations are shown in Table 6. Two patients
withdrew from the study: one patient in the SCS group contracted an infection six weeks after
the implantation and had the SCS removed and another patient suffered from a dural puncture
during SCS implantation, subsequently dying from a subdural hematoma.6 The NNH is 11,
which is significant because it means that if 11 patients are exposed to SCS implantation, an
average of one more patient will have an adverse event that they would not have had otherwise.
Detailed calculations can be seen in Table 7.
Table 5- Slangen, et al.6 Treatment outcomes
SCS Group
Treatment success
13/22 (59%)
> 50% reduction on
9/22 (41%)
NRS for daytime pain
> 50% reduction on
8/22 (36%)
NRS for nighttime pain

Control Group
1/14 (7%)
0/14 (0%)

P-Value
P < 0.009*
P < 0.001**

1/14 (7%)

P < 0.01***

*P < 0.009, significant treatment effect between groups
**P<0.001, significant treatment effect between groups
***P<0.01, significant treatment effect between groups

Table 6- Calculations for treatment success from Slangen, et al.
Relative benefit
Absolute benefit
increase (RBI)
increase (ABI)
EER- CER
CER
EER
EER - CER
CER
0.07

0.59

7.43

0.52

Number needed to
treat (NNT)
1/ABI
2
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Table 7- Calculations for harm from Slangen, et al.
Relative risk
increase (RRI)
EER- CER
CER
EER
CER
0
0.09

Absolute risk
increase (ARI)

Number needed
to harm (NNH)

EER - CER

1/ARI

0.09

11

DISCUSSION
Diabetes is a very common condition and if uncontrolled can come with an array of
complications, including PDPN.2 While medical treatment is an option, it is not always the
safest, not always cost effective, and more importantly for patients it does not always relieve
pain. This review evaluates an alternative treatment for painful diabetic peripheral neuropathy:
spinal cord stimulation. Each study discussed contains limitations. First, this study was restricted
to severe peripheral neuropathic pain that was only located in the lower extremities. Spinal cord
stimulation as a treatment for mild neuropathic pain or pain in the upper extremities was not
addressed, and the results cannot be generalized. In addition, these studies evaluated spinal cord
stimulation for patients that have suffered from pain for a long time, in some cases many years,
and these patients have already failed best medical therapy. It is unknown if SCS would be an
effective treatment in patients with severe pain that have not tried BMT for as long or do not use
BMT in combination with the stimulator. Lastly, in the two RCTs, there have not been published
studies following these patients after the final six month follow up. It is unknown if the spinal
cord stimulators continued to be effective or if they caused any long-term complications.
Spinal cord stimulators have been studied for a variety of indications, including: failed
back surgery syndrome, complex regional pain syndrome, intractable angina, neuropathic pain
secondary to HIV, and neuropathic pain secondary to chemotherapy.3 Caution is recommended
in patients with coagulopathy, pacemakers, and certain psychological conditions. An active
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systemic or local infection is a contraindication for SCS trial and implantation (aside from HIV),
but the implantation can be performed once the infection is cleared.3
Studies involving spinal cord stimulators are limited in terms of their concealment and
blinding. First, patients receiving BMT only knew that they were not receiving the spinal cord
stimulator because it is unethical to undergo a surgical procedure and implant a device that
would not be used. Likewise, patients receiving the spinal cord stimulator knew that they were
receiving the experimental treatment, because it is unethical to perform a surgery without the
patients’ knowledge. In the De Vos, et al. RCT, patients in the control group were offered to
receive SCS therapy at the conclusion of the study if they desired it.5
CONCLUSION
All three studies demonstrated that spinal cord stimulation is an effective alternative
treatment for severe painful diabetic peripheral neuropathy in patients over the age of 18 that
have failed best medical therapy. The complications of diabetes can be very debilitating and
more concrete evidence of an effective treatment is necessary. Further studies should address
patients with diabetes that are experiencing other types of neuropathic pain, including upper
extremity peripheral neuropathy and more proximal neuropathy that affects the thighs, hips, and
buttocks.1 Patients may also experience autonomic neuropathy affecting the digestive tract,
sexual response, the heart, and the lungs.1 Treatments should be evaluated for all types of
neuropathy. Along with this, the safety of a spinal cord stimulator being placed higher on the
spine will have to be evaluated. This will allow the stimulator to relieve symptoms along other
areas of the body. Despite the range of use that spinal cord stimulation is being evaluated for and
the success presented in this review, it is still a fairly new subject that will require expanded
research before it can be used as common practice in treating neuropathic pain.
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